HC 017 AA

Drug Profile

HC 017 AA

Alternative Names: HC017AA

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HCell
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alopecia areata
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia areata

Most Recent Events

  • 15 Jan 2018 Preclinical trials in Alopecia areata (In children, In adolescents) in South Korea (Topical)
  • 15 Jan 2018 HC 017 AA receives Orphan Drug status for Alopecia areata (In children, In adolescents) in USA
  • 15 Jan 2018 HCell plans a clinical trial for Alopecia aerata (In children; In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top